Evidence map›Paper›PMID 35565307›Full record

ReviewCancers2022

The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies.

Malcolm Holterhus, Bianca Altvater, Sareetha Kailayangiri, Claudia Rossig

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Malcolm HolterhusDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, 48149 Muenster, Germany.
Bianca AltvaterDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0003-4936-4879
Sareetha KailayangiriDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0001-7383-7715
Claudia RossigDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0002-8672-5285
University Hospital Münster · DE

Funding

Federal Ministry of Education and Research 01EN2007AGerman Cancer Aid 111975LifeSciences.NRW EFRe-0801764
6 · The paper itself

Abstract

Common pediatric solid cancers fail to respond to standard immuno-oncology agents relying on preexisting adaptive antitumor immune responses. The adoptive transfer of tumor-antigen specific T cells, such as CAR-gene modified T cells, is an attractive strategy, but its efficacy has been limited. Evidence is accumulating that local barriers in the tumor microenvironment prevent the infiltration of T cells and impede therapeutic immune responses. A thorough understanding of the components of the functional compartment of the tumor microenvironment and their interaction could inform effective combination therapies and novel engineered therapeutics, driving immunotherapy towards its full potential in pediatric patients. This review summarizes current knowledge on the cellular composition and significance of the tumor microenvironment in common extracranial solid cancers of childhood and adolescence, such as embryonal tumors and bone and soft tissue sarcomas, with a focus on myeloid cell populations that are often present in abundance in these tumors. Strategies to (co)target immunosuppressive myeloid cell populations with pharmacological anticancer agents and with selective antagonists are presented, as well as novel concepts aiming to employ myeloid cells to cooperate with antitumor T cell responses.

Indexed as

cellular immunotherapytumor-associated macrophagestumor microenvironment

Identifiers

PMID35565307
PMCPMC9105669
OpenAlexW4280629071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.